Search results for "From ACP Internist Weekly"
USPSTF lowers age for starting diabetes screening from 40 to 35 years
Primary care clinicians should screen all overweight or obese adults ages 35 to 70 years for diabetes and prediabetes and should offer interventions for those with either condition, the U.S. Preventive Services Task Force (USPSTF) recently recommended.
https://diabetes.acponline.org/archives/2021/09/10/6.htm
10 Sep 2021
Nearly 50% of older U.S. adults reported taking aspirin preventively
A study of National Health and Nutrition Examination Survey data from 2011 to 2018 found that 46.7% of respondents ages 60 years and older used aspirin for primary or secondary cardiovascular disease prevention and suggested potential overuse in certain groups.
https://diabetes.acponline.org/archives/2021/07/09/7.htm
9 Jul 2021
New recommendations advise on adding SGLT-2 inhibitors and GLP-1 receptor agonists
A new guideline from The BMJ strongly recommends sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with diabetes and established cardiovascular and chronic kidney disease, in addition to offering weaker support for starting glucagon-like peptide-1 (GLP-1) receptor agonists in this same patient population.
https://diabetes.acponline.org/archives/2021/06/11/7.htm
11 Jun 2021
CGM decreased HbA1c levels, hypoglycemia in patients with type 2 diabetes
Two industry-supported studies of continuous glucose monitoring (CGM) found encouraging results in patients with type 2 diabetes, leading editorialists to call for broadened access to the technology in this population, particularly in primary care.
https://diabetes.acponline.org/archives/2021/06/11/6.htm
11 Jun 2021
Racial, economic disparities found in use of SGLT2 inhibitors
Although use of sodium-glucose cotransporter-2 (SGLT2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.
https://diabetes.acponline.org/archives/2021/05/14/8.htm
14 May 2021
Type of insulin may affect hypoglycemia rates in older adults with type 2 diabetes, study finds
The risk of hospital visits for hypoglycemia was lower with long-acting insulin analogs versus neutral protamine Hagedorn (NPH) insulin in a retrospective study of Medicare patients.
https://diabetes.acponline.org/archives/2021/03/12/8.htm
12 Mar 2021
Group-based lifestyle intervention reduced risk of type 2 diabetes
Participants in the Norfolk Diabetes Prevention Study who underwent multiple educational group sessions that included 50-minute sessions of supervised physical activity had significantly lower odds of type 2 diabetes during a mean follow-up of two years compared to those who received usual care.
https://diabetes.acponline.org/archives/2020/11/13/9.htm
13 Nov 2020
Once-weekly insulin had similar effects to daily insulin in type 2 diabetes, industry-funded trial finds
HbA1c levels improved by more than a point in insulin-naive patients with inadequately controlled type 2 diabetes who were randomized to a weekly 70-U dose of an investigational insulin.
https://diabetes.acponline.org/archives/2020/10/09/8.htm
9 Oct 2020
Regular use of PPIs linked to increased risk of type 2 diabetes
In an analysis of the Nurses' Health and Health Professionals studies, regular users of proton-pump inhibitors (PPIs) had a 24% higher risk of diabetes than nonusers, with longer duration of use associated with greater risk.
https://diabetes.acponline.org/archives/2020/10/09/9.htm
9 Oct 2020
SGLT-2 inhibitors associated with lower risk of gout vs. GLP-1 receptor agonists
In a large, propensity-matched study, adult patients with type 2 diabetes who were newly prescribed a sodium-glucose cotransporter-2 (SGLT-2) inhibitor had a lower rate of incident gout than those newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist.
https://diabetes.acponline.org/archives/2020/02/14/7.htm
14 Feb 2020